Key Benefits
-
Increased Stability
LNPs protect mRNA from degradation, ensuring integrity and effective delivery -
Enhanced Delivery
Optimized LNPs enhance cellular uptake and targeted delivery -
Reduced Immunogenicity
Reduced immunogenicity minimizes unwanted immune responses
Service Details
Catalog | Capping and modification | Gene | Quantity | Timeline(Business days) |
---|---|---|---|---|
mRNA-LNP | Custom mRNA Cap1 in LNP | Custom gene or off-the-shelf | 100μg-20mg | 10-25 |
*Additional time (~2-3 weeks ) for custom gene synthesis
mRNA grade and QC standard
QC category | QC item | Method | Specification | Research Grade |
---|---|---|---|---|
mRNA-LNP (On-shelf and Custom) |
RNA Integrity/size | Capillary Electrophoresis | >80% | √ |
Encapsulate Efficiency | Elisa Analyzer | Report | √ | |
Particle size | Dynamic Light Scattering | <120nm | √ | |
Particle Uniformity | Dynamic Light Scattering | <0.2 | √ | |
Concentration | Capillary Electrophoresis | Encapsulated mRNA >0.2mg/mL | √ |
PackGene’s quality control (QC) testing of mRNA lipid nanoparticles (LNPs) includes measurement of various parameters to ensure their quality, safety, and efficacy. Some of the essential QC tests for mRNA LNP are encapsulation efficiency, particle size, and uniformity.
Performance
-
mRNA-LNP performance
EGFP mRNA (Cap1) -LNP
Z Ave. Dia (nm) 76.8 PDI PDI Encapsulation Efficiency 93.91% -
mRNA-LNP Gene Delivery in Animal